Cullinan Therapeutics, Inc. (CGEM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 7M 14M 21M Q1 '21: 18.9M Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 Q3 '22 Q4 '22

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-90M 0 90M 180M 270M Q1 '20: -5.5M Q2 '20: -14.1M Q3 '20: -11.5M Q4 '20: -29.2M Q1 '21: 1.4M Q2 '21: -16.6M Q3 '21: -18.4M Q4 '21: -34.3M Q1 '22: -32.7M Q2 '22: 239.7M Q3 '22: -29.8M Q4 '22: -32.6M Q1 '23: -62.8M Q2 '23: -37.6M Q3 '23: -45.2M Q4 '23: -45.5M Q1 '24: -43M Q2 '24: -50M Q3 '24: -48.9M Q4 '24: -55M Q1 '25: -55M Q2 '25: -75.8M Q3 '25: -55.6M Q4 '25: -55.3M Q1 '26: -53.7M Q2 '26: -57.3M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income Quarterly

-120M -60M 0 60M 120M 180M Q1 '20: -5M Q2 '20: -8.6M Q3 '20: -9.9M Q4 '20: -28.3M Q1 '21: -70K Q2 '21: -15.6M Q3 '21: -17.4M Q4 '21: -32.5M Q1 '22: -12.1M Q2 '22: 174.9M Q3 '22: -24.8M Q4 '22: -26.8M Q1 '23: -58M Q2 '23: -32.2M Q3 '23: -39.2M Q4 '23: -23.8M Q1 '24: -37.1M Q2 '24: -42M Q3 '24: -40.6M Q4 '24: -47.6M Q1 '25: -48.5M Q2 '25: -70.1M Q3 '25: -50.6M Q4 '25: -50.7M Q1 '26: -49.7M Q2 '26: -53.7M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '20: -5M Q2 '20: -6.2M Q3 '20: -9.1M Q4 '20: -9.4M Q1 '21: -1.5M Q2 '21: -16.2M Q3 '21: -10.6M Q4 '21: -15.2M Q1 '22: -21.9M Q2 '22: -25.4M Q3 '22: -54.4M Q4 '22: -25M Q1 '23: -51M Q2 '23: -31M Q3 '23: -34.1M Q4 '23: -18.1M Q1 '24: -38.2M Q2 '24: -36.3M Q3 '24: -34.1M Q4 '24: -36.6M Q1 '25: -43.2M Q2 '25: -57.6M Q3 '25: -36.9M Q4 '25: -38.1M Q1 '26: -46M Q2 '26: -38.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '20: -5M Q2 '20: -6.3M Q3 '20: -9.1M Q4 '21: -15.2M Q1 '22: -21.9M Q2 '22: -25.4M Q3 '22: -54.6M Q4 '22: -25.9M Q1 '23: -51.2M Q2 '23: -31.1M Q3 '23: -34.1M Q4 '23: -18.1M Q1 '24: -38.2M Q2 '24: -36.3M Q3 '24: -34.1M Q4 '24: -36.6M Q4 '25: -38.1M Q2 '20 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q2 '21: 43.3M Q3 '21: 43.4M Q1 '22: 44.4M Q2 '22: 46.4M Q3 '22: 45.6M Q1 '23: 40.7M Q2 '23: 40M Q3 '23: 42.7M Q1 '24: 43M Q2 '24: 55.1M Q3 '24: 58.3M Q2 '21 Q1 '22 Q3 '22 Q2 '23 Q1 '24 Q3 '24

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '20: -2.60 Q1 '21: -2.33 Q2 '21: -2.25 Q3 '21: -2.15 Q4 '21: -1.52 Q1 '22: -1.79 Q2 '22: 2.34 Q3 '22: 2.20 Q4 '22: 2.38 Q1 '23: 1.23 Q2 '23: -3.36 Q3 '23: -3.73 Q4 '23: -3.69 Q1 '24: -3.13 Q2 '24: -3.06 Q3 '24: -2.84 Q1 '21 Q3 '21 Q1 '22 Q3 '22 Q1 '23 Q3 '23 Q1 '24 Q3 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.